Log in Free sign up

Kezar Life Sciences (KZR) News and press releases

News

From Benzinga Pro

Short Volatility Alert: Kezar Life Sciences, Inc.

Short Ideas, Trading Ideas

On Tuesday, shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) experienced volatile short activity. After the activity, the stock price went up +43.43% to $8.29. The overall sentiment for KZR has been Bearish.

InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.

Wells Fargo Beefs Up Kezar Life Price Target - Read Why

Analyst Color, Biotech, News, Health Care, Price Target, Small Cap, Analyst Ratings, Movers, Trading Ideas, General

Dow Dips Over 400 Points; Crude Oil Rises 2%

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks turned sharply lower toward the end of trading, with the Dow Jones dropping more than 400 points on Tuesday.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Nasdaq Turns Lower; Kezar Life Sciences Shares Jump

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks pared gains midway through trading, with the Nasdaq Composite and S&P 500 turning lower on Tuesday.

Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.

Markets Open Higher; US Goods Gap Narrows To $104.3B In May

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded higher this morning, with the Dow Jones gaining over 350 points on Tuesday.

Why Kezar Life Sciences Stock Is Soaring Today

Small Cap, Movers, Trading Ideas

Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging Tuesday after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.

The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives

Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Contracts, Small Cap, FDA, Management, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

Wells Fargo Maintains Overweight on Kezar Life Sciences, Raises Price Target to $17

News, Price Target, Analyst Ratings

Wells Fargo analyst Derek Archila maintains Kezar Life Sciences (NASDAQ:KZR) with a Overweight and raises the price target from $13 to $17.

Why Is Kezar Life Sciences Surging By 78%? 25 Stocks Moving In Tuesday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

12 Health Care Stocks Moving In Monday's After-Market Session

Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate

Biotech, Health Care, Movers & Shakers, Small Cap, General

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

After-Hours Action: Why Kezar Life Sciences Stock Is Soaring

Small Cap, Movers, Trading Ideas

Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging in Monday's after-hours session after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.

Kezar Life Sciences Announces Topline Results From The MISSION Phase 2 Trial Evaluating Zetomipzomib For The Treatment Of Patients With Lupus Nephritis

Biotech, News, FDA, General

11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months 6 of 17 patients (35.2%) achieved a complete renal

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Monday's trading, 1214 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 422 stocks made new 52-week lows.

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More

Biotech, News, Penny Stocks, Small Cap, FDA, IPOs, General

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period.

Press releases

From Benzinga Pro

Thinking about buying stock in Autohome, Bed Bath & Beyond, Kezar Life Sciences, General Electric, or Delta Air Lines?

Opinion, Press Releases

NEW YORK, June 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATHM, BBBY, KZR, GE, and DAL.

Healthcare Breakthroughs: KZR, NMLSF, AGRX, LMLLF Report Latest Advances in Novel Therapeutics for Inflammatory Diseases, Oncology, and Autism

Press Releases, General

NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO's of: Kezar Life Sciences

Thinking about buying stock in Kezar Life Sciences, Evofem Biosciences, Agile Therapeutics, Sutro Biopharma, or Wejo Group?

Opinion, Press Releases

NEW YORK, June 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KZR, EVFM, AGRX, STRO, and WEJO.

Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis

11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months 6 of 17 patients (35.2%) achieved a complete renal response,

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Small Cap, Press Releases

Kezar Life Sciences, Inc.,

Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

Small Cap, Press Releases

Topline data from MISSION Phase 2 trial of zetomipzomib for the treatment of lupus nephritis expected in June 2022, consistent with previous guidance KZR-261 continu

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Small Cap, Press Releases

Kezar Life Sciences, Inc.,

Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis

Small Cap, Press Releases

Most patients saw clinically meaningful improvements in the primary endpoint measure of Total Improvement Score (TIS), but no differentiation from placebo was observed

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Small Cap, Press Releases

Kezar Life Sciences, Inc.,